Prime Medicine, Inc. Common Stock
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that… Read more
Prime Medicine, Inc. Common Stock (PRME) - Net Assets
Latest net assets as of September 2025: $161.82 Million USD
Based on the latest financial reports, Prime Medicine, Inc. Common Stock (PRME) has net assets worth $161.82 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($385.01 Million) and total liabilities ($223.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $161.82 Million |
| % of Total Assets | 42.03% |
| Annual Growth Rate | 156.04% |
| 5-Year Change | 357.52% |
| 10-Year Change | N/A |
| Growth Volatility | 896.69 |
Prime Medicine, Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Prime Medicine, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Prime Medicine, Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Prime Medicine, Inc. Common Stock from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $153.15 Million | +15.09% |
| 2023-12-31 | $133.07 Million | -57.92% |
| 2022-12-31 | $316.27 Million | +32.02% |
| 2021-12-31 | $239.56 Million | +615.66% |
| 2020-12-31 | $33.47 Million | +2309.94% |
| 2019-12-31 | $1.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Prime Medicine, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68461300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $1.00K | 0.00% |
| Other Components | $840.36 Million | 548.72% |
| Total Equity | $153.15 Million | 100.00% |
Prime Medicine, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Prime Medicine, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Kexing Bioproducts Co. Ltd. A
SHG:688136
|
$387.13 Million |
|
Urban Company Limited
NSE:URBANCO
|
$387.17 Million |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
PINK:SBOEF
|
$387.18 Million |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
$387.20 Million |
|
Ridley Corporation Limited
PINK:RIDYF
|
$387.08 Million |
|
Boss Energy Ltd
AU:BOE
|
$387.04 Million |
|
Apollo Micro Systems Limited
NSE:APOLLO
|
$387.02 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
$386.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Prime Medicine, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 133,071,000 to 153,149,000, a change of 20,078,000 (15.1%).
- Net loss of 195,882,000 reduced equity.
- New share issuances of 170,136,000 increased equity.
- Other comprehensive income increased equity by 16,000.
- Other factors increased equity by 45,808,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-195.88 Million | -127.9% |
| Share Issuances | $170.14 Million | +111.09% |
| Other Comprehensive Income | $16.00K | +0.01% |
| Other Changes | $45.81 Million | +29.91% |
| Total Change | $- | 15.09% |
Book Value vs Market Value Analysis
This analysis compares Prime Medicine, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 255.69x to 2.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.01 | $3.71 | x |
| 2020-12-31 | $0.35 | $3.71 | x |
| 2021-12-31 | $2.50 | $3.71 | x |
| 2022-12-31 | $3.25 | $3.71 | x |
| 2023-12-31 | $1.46 | $3.71 | x |
| 2024-12-31 | $1.29 | $3.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Prime Medicine, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -127.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6566.61%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.94x
- Recent ROE (-127.90%) is below the historical average (-96.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -182.07% | 0.00% | 0.00x | 6.26x | $-2.67 Million |
| 2020 | -10.19% | -65.45% | 0.10x | 1.64x | $-6.76 Million |
| 2021 | -69.03% | 0.00% | 0.00x | 1.26x | $-189.32 Million |
| 2022 | -38.52% | -2338.21% | 0.01x | 1.14x | $-153.45 Million |
| 2023 | -148.89% | 0.00% | 0.00x | 1.46x | $-211.44 Million |
| 2024 | -127.90% | -6566.61% | 0.01x | 1.94x | $-211.20 Million |
Industry Comparison
This section compares Prime Medicine, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Prime Medicine, Inc. Common Stock (PRME) | $161.82 Million | -182.07% | 1.38x | $387.10 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |